Beyond Air, Inc. Common Stock (XAIR)
Beyond Air, Inc. (XAIR) is a healthcare company focused on developing and commercializing portable, affordable oxygen therapy devices. It aims to improve respiratory care for patients with chronic lung diseases through its innovative technologies, including its Aerisa platform, which utilizes compressed oxygen and nitric oxide therapy. The company's solutions are designed to enhance patient quality of life while reducing healthcare costs.
Company News
Beyond Air will exercise existing warrants to purchase 1,439,126 shares at $2.21 per share, generating approximately $3.25 million in gross proceeds. The company will simultaneously issue new unregistered warrants and plans to use the funds for clinical programs and operating expenses.
Beyond Air reported Q1 fiscal 2026 results with 157% revenue growth to $1.8 million, but missed analyst estimates. The company expanded international sales, reduced expenses, and made regulatory progress in nitric oxide therapies.
Beyond Air (XAIR) delivered earnings and revenue surprises of 23.40% and 33.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Stay up to date with the latest financial news! Listen to the Wall Street Breakfast podcast on Seeking Alpha, iTunes, and Spotify.
Steelcase Inc. (NYSE: SCS) shares moved higher during Wednesday's session following quarterly results. Steelcase posted upbeat earnings for its third quarter, while sales missed estimates. The company said it sees fourth-quarter adjusted earnings of 19 cents to 23 cents per share on revenue of $765 million to $790 million. Steelcase shares gained...